Newgenivf Group Ltd annual report, Q2 FY2024

Full document

Business Context and Reporting Period

NewGenIVF Group Limited filed a Form 20-F shell company report in connection with the consummation of its business combination on April 3, 2024. The company is a British Virgin Islands business company and became the parent of Legacy NewGenIvf, a Cayman Islands company, through a two-step reincorporation and acquisition merger.

Following the transaction, the group operates fertility clinics primarily in Thailand, Cambodia and Kyrgyzstan. Its principal services are in-vitro fertilization, including traditional IVF and egg donation, and surrogacy and ancillary caring services. The filing was signed on April 9, 2024, and does not constitute a full annual report for a specified fiscal year.

Financial Metrics, Capitalization and Liquidity

  • The filing does not provide a clear consolidated value for revenue, net income, operating margins, cash flow, cash balances, total debt, or liquidity.
  • Historical Legacy NewGenIvf financial statements for 2021 and 2022, interim statements through June 30, 2023, and pro forma combined financial information are incorporated by reference from the Form F-4.
  • As of April 3, 2024, the company had 10,149,386 Class A ordinary shares outstanding and 8,319,988 warrants outstanding.
  • Each warrant is exercisable for one Class A ordinary share at $11.50 per share. The warrants were scheduled to become exercisable on May 3, 2024 and expire on April 3, 2029, subject to their terms.
  • The company issued an aggregate principal amount of $2.0 million of convertible notes to JAK as of the report date. The related financing arrangement permits aggregate notes of up to $3.5 million, subject to additional tranches.
  • The filing states that the deferred underwriting commission owed to Chardan included $1.0 million in cash, 1.5 million additional ordinary shares, and 30% of gross proceeds from post-closing financings until the commission is fully paid within six months of closing.

Material Changes Versus the Prior Comparable Period

  • The principal change was the April 3, 2024 consummation of the business combination, after which Legacy NewGenIvf became a wholly owned subsidiary of NewGenIVF Group Limited.
  • The transaction resulted in a new public-company structure, Nasdaq listings under the symbols NIVF and NIVFW, and the issuance or assumption of significant equity, warrant and convertible-note instruments.
  • The filing reports no significant changes under Item 8.B, but it does not provide a detailed operating-period comparison.
  • Marcum Asia was dismissed as auditor of the SPAC effective April 3, 2024, and Onestop Assurance PAC was engaged as auditor of PubCo. Marcum Asia’s reports contained an explanatory paragraph concerning substantial doubt about the SPAC’s ability to continue as a going concern.
  • A second Thailand clinic was expected to open in 2024; the filing does not provide an updated opening date or financial impact.

Guidance, Outlook, Risks and Unusual Items

  • No quantitative revenue, earnings, cash-flow or other financial guidance is provided in the filing.
  • Management’s forward-looking statements are subject to risks incorporated by reference from the Form F-4, including risks associated with the fertility and surrogacy businesses, international operations, regulation, third-party relationships, financing, execution of the business plan and the post-business-combination structure.
  • The company leases its principal office and facilities in Thailand, Cambodia and Kyrgyzstan. It also entered into a lease for a planned second Thailand clinic.
  • The company states that it is not currently party to any material legal or administrative proceedings, while noting that ordinary-course litigation could affect results through defense costs, settlements and management distraction.
  • There were no reported disagreements or reportable events between PubCo and Marcum Asia through April 3, 2024. The filing does not provide a current assessment of PubCo’s post-closing internal controls or liquidity beyond the transaction disclosures.
  • Ownership is concentrated: the CEO and chair-related shareholder group held approximately 40.4% of outstanding shares as a group, based on the beneficial ownership table.

Most Important Facts for Investors to Verify

  1. Review the incorporated Form F-4 financial statements and pro forma information for actual revenue, profitability, cash flow, debt, liquidity and historical trends.
  2. Review the terms, conversion mechanics, interest, maturity and potential dilution of the $2.0 million issued convertible notes and any remaining $1.5 million financing capacity.
  3. Confirm the amount and timing of deferred underwriting obligations to Chardan, including the $1.0 million cash payment, 1.5 million shares and 30% financing-proceeds entitlement.
  4. Assess dilution from the 8,319,988 warrants, the convertible notes, additional representative shares, lock-ups and other transaction-related securities.
  5. Verify the regulatory and operational status of the IVF, surrogacy and ancillary-care businesses across Thailand, Cambodia and Kyrgyzstan.
  6. Evaluate the going-concern and liquidity implications of the former SPAC structure, post-closing financing needs and the auditor transition to Onestop Assurance PAC.